Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Corning Incorporated (GLW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Corning IncorporatedTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Corning Incorporated vs Vertex Pharmaceuticals Incorporated — how do they compare? Corning Incorporated trades at $164.1 (market cap $135.89B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Corning Incorporated and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Corning Incorporated pays a 0.71% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

GLWVRTX
Market Cap
$135.89B$132.79B
Sector
TechnologyHealth
52-Week High
$255.79$529.65
52-Week Low
$64.52$376.62
Enterprise Value
$142.77B$126.92B
Dividend Yield
0.71%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Corning Incorporated

No Aura AI signal available yet.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.

Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Corning Incorporated

Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.

Read more on GLW

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX